Novartis (NVS) announced positive final results from APPLAUSE-IgAN, a Phase III study evaluating Fabhalta in adults living with IgA nephropathy, IgAN. Fabhalta, an oral alternative complement pathway inhibitor, demonstrated statistically significant, clinically meaningful superiority compared to placebo in slowing IgAN progression measured by annualized total slope of estimated glomerular filtration rate decline over two years. In APPLAUSE-IgAN, Fabhalta was well tolerated with a favorable safety profile in line with previously reported data. Full data from the APPLAUSE-IgAN final analysis will be presented at future medical meetings.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Trump Weekly: Generics to be excluded from pharma tariff plan
- Trump Trade: GoodRx, others in talks with White House to join TrumpRx
- GoodRx, others in talks with White House to join TrumpRx, Reuters reports
- Trump Trade: Generics to be excluded from pharma tariff plan
- Generics to be excluded from Trump’s pharma tariff plan, WSJ reports